AstraZeneca is the latest major drugmaker to strike a deal with the Trump administration on lowering U.S. drug prices https://t.co/3H5nCVbMoC ...

The agreement follows last week's deal with Pfizer. ...

AstraZeneca PLC looks poised to announce a deal with U.S. President Donald Trump that's focused on lowering drug prices, in a move that would see the British drugmaker follow in the footsteps of Pfize... ...

U.S. President Donald Trump participates in a bilateral meeting with Finland's President Alexander Stubb (not pictured), in the Oval office at the White House in Washington, D.C., U.S., Oct. 9, 2025.The Trump administration and AstraZeneca have reached an agreement for the U.K.-based pharmaceutical giant to cut drug prices in the U.S., MSNBC reported Friday.The deal with AstraZeneca would follow a similar pact with U.S. drugmaker Pfizer, which was announced late last month.President Donald Trump and AstraZe ...

AstraZeneca is expected to announce a deal with Trump to slash drug prices, people familiar with the plans said, making it the second pharmaceutical company to strike an agreement to advance one of the president's key health priorities https://t.co/TJppQUDFqI ...

Wall Street is looking to U.S. drugmaker Eli Lilly and Anglo-Swedish rival AstraZeneca as the potential next in line after Pfizer struck a deal with Donald Trump's administration to lower drug prices ... ...

AstraZeneca has commenced construction of its $4.5bn active pharmaceutical ingredient (API) manufacturing facility in Virginia. The site, which is located near Charlottesville, will produce APIs for medicines across its cardiovascular, obesity, oncology and metabolic disease portfolio. This includes drugs from the company’s mid-to-late-stage pipeline – namely its Eccogene-partnered glucagon-like peptide-1 receptor agonist (GLP-1RA) pill, AZD5004/ ECC-5004, as well as hypertension med baxdrostat and low-d ...

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Today, a brief rundown of news involving AstraZeneca and Ascenta Capital, as well as updates from Expedition Therapeutics, Ferring Pharmaceuticals and Sanofi that you may have missed. AstraZeneca has upped its planned investment in a new drug manufacturing facility in Virginia. In a Thursday announcement, the company said it’s adding $500 million to a previously ...

来源：市场资讯 （来源：医趋势） 从巨头的内部攻坚到跨界联盟，这场变革正在改写医药研发的底层逻辑。 01、今年第三项合作，阿斯利康AI加速度 AI赋能新药研发，预计可将研发周期平均缩短1/2至2/3，研发投入降低10%，同时提高新药研发成功 率。因此，全球顶级药企纷纷布局AI。例如，赛诺菲曾立志成为首家由AI大规模驱动的大型药企。 作为药企中的"AI先行者"，阿斯利康凭借"技术沉淀-标准输出-实践落地-合作拓展"的递进逻辑，持续夯 实其在该领域的领先地位。其此次5.55亿美元的新赌注实则是厚积薄发的必然。 10月6日，阿斯利康（AstraZeneca）宣布与美国生物技术公司Algen Biotechnologies签署一项价值5.55亿 美元的合作协议，旨在借助后者的先进人工智能（AI）平台，推动免疫学领域新治疗靶点的发现。 协议规定Algen将利用其名为"AlgenBrain"的平台，为阿斯利康开展早期药物研发工作。合作的核心目标 是"通过前沿的CRISPR基因调控技术与AI驱动的药物发现手段"，开发一系列下一代免疫学疗法。 阿斯利康在声明中强调，此次合作使其获得了"针对合作期间确定并筛选出的特定靶点组合， ...

AstraZeneca broke ground on a new plant in Virginia on Thursday and said it would spend $4.5 billion on the facility as drugmakers look to respond to President Donald Trump's call for more medicines to be made in the U.S. and at lower costs. ...